Tc-99m-galactosyl-neoglycoalbumin: in vivo characterization of receptor-mediated binding to hepatocytes.

PubWeight™: 0.84‹?›

🔗 View Article (PMID 6701314)

Published in Radiology on April 01, 1984

Authors

D R Vera, K A Krohn, R C Stadalnik, P O Scheibe

Articles by these authors

Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys (1992) 2.61

Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys (1996) 2.12

Validity of microsphere depositions for regional myocardial flows. Am J Physiol (1987) 2.00

Molecular and particulate depositions for regional myocardial flows in sheep. Circ Res (1990) 1.74

Imaging and treatment of B-cell lymphoma. J Nucl Med (1990) 1.68

Contribution of labeled carbon dioxide to PET imaging of carbon-11-labeled compounds. J Nucl Med (1992) 1.64

[(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging (2003) 1.62

Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol (1989) 1.43

Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest (1983) 1.42

Characterization of iodovinylmisonidazole as a marker for myocardial hypoxia. J Nucl Med (1993) 1.39

Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys (1989) 1.38

Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep (1984) 1.35

Myocardial extraction and retention of 2-iododesmethylimipramine: a novel flow marker. Am J Physiol (1986) 1.33

Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys (1995) 1.29

Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res (1987) 1.18

Validation of in vivo receptor measurements via in vitro radioassay: technetium-99m-galactosyl-neoglycoalbumin as prototype model. J Nucl Med (1991) 1.15

Measurement of receptor concentration and forward-binding rate constant via radiopharmacokinetic modeling of technetium-99m-galactosyl-neoglycoalbumin. J Nucl Med (1991) 1.15

Production of [11C]CH3I by single pass reaction of [11C]CH4 with I2. Nucl Med Biol (1997) 1.11

Thrombotic complications of umbilical artery catheters: A clinical and radiographic study. Pediatrics (1975) 1.09

Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: analysis of the FDG lumped constant. J Nucl Med (1998) 1.09

Experimental radioimmunotherapy of murine lymphoma with 131I-labeled anti-T-cell antibodies. Cancer Res (1986) 1.06

Acute mesenteric infarction. Am J Roentgenol Radium Ther Nucl Med (1971) 1.05

Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematical analysis. J Nucl Med (1998) 1.05

[18F]fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med (2001) 1.05

Hypoxia imaging-directed radiation treatment planning. Eur J Nucl Med Mol Imaging (2006) 1.04

Scintigraphy in the diagnosis of osteonecrosis. Clin Orthop Relat Res (1978) 1.02

Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. Cancer Res (1992) 1.01

Radionuclide imaging of the biliary tree. Surg Clin North Am (1981) 1.01

Differences in the sites of iodination of proteins following four methods of radioiodination. Biochim Biophys Acta (1977) 1.01

Experimental radiotherapy of murine lymphoma with 131I-labeled anti-Thy 1.1 monoclonal antibody. Cancer Res (1985) 1.00

Value and limitations of scanning of the biliary tract. Surg Gynecol Obstet (1980) 0.99

Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med (1998) 0.98

Scintigraphic imaging of a blind-ending ureteral duplication. J Nucl Med (1975) 0.96

A radiosynthesis of fluorine-18 fluoromisonidazole. J Nucl Med (1989) 0.95

Technetium-99m NGA functional hepatic imaging: preliminary clinical experience. J Nucl Med (1985) 0.94

Vascularity of the femoral head. Tc diphosphonate scintigraphy validated with tetracycline labeling. Clin Orthop Relat Res (1977) 0.94

Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging. J Nucl Med (1996) 0.94

Quantitative assessment of hepatocellular function through in vivo radioreceptor imaging with technetium 99m galactosyl human serum albumin. Hepatology (1993) 0.93

Kinetic characterization of hexokinase isoenzymes from glioma cells: implications for FDG imaging of human brain tumors. Nucl Med Biol (2001) 0.91

Synthesis and characterization of congeners of misonidazole for imaging hypoxia. J Nucl Med (1987) 0.90

Hepatobiliary scintigraphy with technetium-99m disofenin in the evaluation of neonatal cholestasis. J Pediatr Gastroenterol Nutr (1988) 0.90

Kinetic quantitation of cerebral PET-FDG studies without concurrent blood sampling: statistical recovery of the arterial input function. IEEE Trans Med Imaging (2009) 0.90

Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies. J Nucl Med (1997) 0.90

Classic and contemporary imaging of coccidioidomycosis. AJR Am J Roentgenol (1981) 0.89

Sentinel node imaging via a nonparticulate receptor-binding radiotracer. J Nucl Med (1997) 0.89

False-positive results of I-131 whole-body scans in patients with thyroid cancer. Semin Nucl Med (1995) 0.89

Noninvasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography. J Nucl Med (1992) 0.89

Utilization of labeled thymidine in DNA synthesis: studies for PET. J Nucl Med (1990) 0.89

Hepatic scintiangiographic patterns. Radiology (1974) 0.88

Unsatisfactory biologic behavior of I-fibrinogen labeled by the chloramine-T method. J Lab Clin Med (1973) 0.88

Technetium-99m galactosyl-neoglycoalbumin: preparation and preclinical studies. J Nucl Med (1985) 0.87

Critical evaluation of hepatic scintiangiography for neoplastic tumors of the liver. J Nucl Med (1975) 0.87

Tc-99m galactosyl-neoglycoalbumin: in vitro characterization of receptor-mediated binding. J Nucl Med (1984) 0.87

Clinical evaluation of 99mTc-pyridoxylideneglutamate for hepatobiliary scanning. Am J Surg (1976) 0.87

Further characterization of 4-bromomisonidazole as a potential detector of hypoxic cells. Radiat Res (1985) 0.86

Use of I-131 labeled, murine Fab against a high molecular weight antigen of human melanoma: preliminary experience. Radiology (1985) 0.86

Receptor measurements via Tc-GSA kinetic modeling are proportional to functional hepatocellular mass. J Nucl Med (2001) 0.86

Immunoreactivity assay for labeled anti-melanoma monoclonal antibodies. J Nucl Med (1986) 0.86

Iodophenylpentadecanoic acid-myocardial blood flow relationship during maximal exercise with coronary occlusion. J Nucl Med (1990) 0.85

Bone island: scintigraphic findings and their clinical application. Can Assoc Radiol J (1995) 0.84

2-[C-11]thymidine imaging of malignant brain tumors. Cancer Res (1999) 0.84

Radioprotection of normal tissues against gamma rays and cyclotron neutrons with WR-2721: LD50 studies and 35S-WR-2721 biodistribution. Radiat Res (1984) 0.84

Importance of pre-treatment radiation absorbed dose estimation for radioimmunotherapy of non-Hodgkin's lymphoma. Nucl Med Biol (1997) 0.84

Molecular imaging of regional brain tumor biology. J Cell Biochem Suppl (2002) 0.84

Comparison of ultrasonography, computerized tomography, and radionuclide imaging in the diagnosis of acute and chronic cholecystitis. Am J Surg (1982) 0.84

In vitro measurement of avidity of radioiodinated antibodies. Int J Rad Appl Instrum B (1987) 0.84

Quantitation of presynaptic cardiac sympathetic function with carbon-11-meta-hydroxyephedrine. J Nucl Med (1998) 0.84

Kinetic analysis of 2-[11C]thymidine PET imaging studies: validation studies. J Nucl Med (1999) 0.84

In vitro quantification of asialoglycoprotein receptor density from human hepatic microsamples. Methods Enzymol (1994) 0.84

Kinetic sensitivity of a receptor-binding radiopharmaceutical: technetium-99m galactosyl-neoglycoalbumin. J Nucl Med (1989) 0.83

Preliminary studies of monoclonal antibody lymphoscintigraphy in malignant melanoma. J Nucl Med (1987) 0.83

Binding of the hypoxia tracer [3H]misonidazole in cerebral ischemia. Stroke (1987) 0.83

Radiation doses in the surroundings of patients undergoing nuclear medicine diagnostic studies. Health Phys (2005) 0.82

Identifiability analysis of an in vivo receptor-binding radiopharmacokinetic system. IEEE Trans Biomed Eng (1985) 0.81

Comparison of radiolabeled bleomycins and gallium citrate in tumor-bearing mice. J Nucl Med (1977) 0.81

Technetium-99m pyridoxylideneglutamate (P.G.) cholescintigraphy. Radiology (1976) 0.81

A musculoskeletal radiologist's view of nuclear medicine. Semin Nucl Med (1997) 0.81

A graphical analysis method to estimate blood-to-tissue transfer constants for tracers with labeled metabolites. J Nucl Med (1996) 0.81

Evaluation of hepatocellular function by way of receptor-mediated uptake of a technetium-99m-labeled asialoglycoprotein analog. Hepatology (1994) 0.81

Unilateral absence or near absence of pulmonary perfusion on lung scanning. Semin Nucl Med (1995) 0.81

Segmental biliary obstruction: diagnostic significance of bile duct crowding. AJR Am J Roentgenol (1981) 0.81

Comparison of fluorine-18-fluorodeoxyglucose and tritiated fluoromisonidazole uptake during low-flow ischemia. J Nucl Med (1995) 0.81

Tumor imaging with a macromolecular paramagnetic contrast agent: gadopentetate dimeglumine-polylysine. Acad Radiol (1995) 0.81

Tumor receptor imaging: proceedings of the National Cancer Institute workshop, review of current work, and prospective for further investigations. Clin Cancer Res (1995) 0.80